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ABSTRACT
Background: There is much speculation with regard to the poten-
tial cardioprotective benefits of equol, a microbial-derived metabo-
lite of the isoflavone daidzein, which is produced in the large
intestine after soy intake in 30% of Western populations. Although
cross-sectional and retrospective data support favorable associations
between the equol producer (EP) phenotype and cardiometabolic
health, few studies have prospectively recruited EPs to confirm this
association.
Objective: The aim was to determine whether the acute vascular
benefits of isoflavones differ according to EP phenotype and sub-
sequently investigate the effect of providing commercially produced
S-(–)equol to non-EPs.
Design: We prospectively recruited male EPs and non-EPs (n = 14/
group) at moderate cardiovascular risk into a double-blind, placebo-
controlled crossover study to examine the acute effects of soy
isoflavones (80-mg aglycone equivalents) on arterial stiffness
[carotid-femoral pulse-wave velocity (cfPWV)], blood pressure,
endothelial function (measured by using the EndoPAT 2000;
Itamar Medical), and nitric oxide at baseline (0 h) and 6 and 24 h
after intake. In a separate assessment, non-EPs consumed 40 mg
S-(–)equol with identical vascular measurements performed 2 h
after intake.
Results: After soy intake, cfPWV significantly improved in EPs at
24 h (cfPWV change from 0 h: isoflavone,20.26 0.2 m/s; placebo,
0.6 6 0.2 m/s; P , 0.01), which was significantly associated with
plasma equol concentrations (R = 20.36, P = 0.01). No vascular
effects were observed in EPs at 6 h or in non-EPs at any time point.
Similarly, no benefit of commercially produced S-(–)equol was ob-
served in non-EPs despite mean plasma equol concentrations reach-
ing 3.2 mmol/L.
Conclusions: Acute soy intake improved cfPWV in EPs, equating
to an 11–12% reduced risk of cardiovascular disease if sustained.
However, a single dose of commercially produced equol had no
cardiovascular benefits in non-EPs. These data suggest that the EP
phenotype is critical in unlocking the vascular benefits of equol in
men, and long-term trials should focus on confirming the implica-
tions of EP phenotype on cardiovascular health. This trial was reg-
istered at clinicaltrials.gov as NCT01530893. Am J Clin Nutr
doi: 10.3945/ajcn.115.125690.
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INTRODUCTION
There is growing interest in the cardioprotective role of the
microbial-derived isoflavone metabolite equol, which is pro-
duced by 20–30% of Western (1) and 50–60% of Asian (2)
populations after consumption of daidzein-rich soy foods. This
has largely been stimulated by favorable associations in cross-
sectional analysis between the equol producer (EP)4 phenotype
and established markers of vascular function, including blood
pressure (BP) (3), arterial stiffness, and endothelial function (4)
and, likewise, biomarkers relevant to vascular health including
lipids (3, 5), inflammatory biomarkers, and nitric oxide (NO) (3,
6, 7). In support of these associations, pharmacokinetic studies
have indicated that equol has a higher systemic bioavailability
and slower elimination rate (8, 9), and in vitro studies have re-
ported greater antioxidant (10, 11) and vasodilator capacities
than its precursor, daidzein (12, 13). Retrospective analysis of
isoflavone intervention studies [lasting between 4 wk (14) and
1 y (7, 15)] also identified that the EP phenotype was associated
with improvements in BP (4, 7, 15), arterial stiffness (7), and
endothelial function (14). However, to date, few trials have re-
cruited men or have been designed to prospectively determine
the importance of the EP phenotype on vascular function by
recruiting on the basis of EP phenotype. As a consequence, the
ability to robustly interpret the importance of EP phenotype, or
equol per se, remains unclear. In consideration of the vascular
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disease risk in men (16), studies assessing the importance of the
EP in men should also be a focus.
In the 2 previous studies that prospectively recruited female
postmenopausal EPs and provided isoflavone interventions
lasting 8 wk (4) and 6 mo (17), the results contradicted the cross-
sectional and retrospective associations previously reported, with
BP, arterial stiffness, and endothelial function being unaltered (4,
17). In both instances, however, the relevance of the results is
difficult to interpret. In one of the studies (4) the synthetic steroid
hormone drug tibolonewas coadministered, which has previously
been shown to influence endothelial function (18, 19), whereas
the more recent study by Liu et al. (17) did not include a matched
non-EP group to compare the relative efficacy and provided an
active placebo control (milk), which may explain the improve-
ments in BP and flow-mediated dilation after receiving the
placebo (17). To date, the acute or longer-term vascular benefits
of the EP phenotype are largely unknown.
An alternative approach to harness the potential vascular
benefits of equol per se has also emerged, with the development
of exogenously produced equol products, either chemically
synthesized, or more recently produced through soy germ fer-
mentation by an equol-producing lactic acid bacterium Lacto-
coccus 20-92 (SE5-OH; described further in references 8 and
20). Recently, the effect of this commercial bacterium–produced
S-(–)equol on markers of cardiovascular disease (CVD) risk
were assessed, with reductions in glycated hemoglobin, LDL
cholesterol, and arterial stiffness observed in postmenopausal
non-EPs after daily intake of a 10-mg S-(–)equol supplement for
12 wk (21). Because pharmacokinetic data have previously
shown that commercially produced S-(–)equol is rapidly ab-
sorbed, with peak plasma concentrations within 1–2 h after
administration (8, 9), further investigations are required to es-
tablish the acute vascular response at these peak concentrations.
We therefore prospectively recruited on the basis of EP
phenotype and identified nonmedicated men with moderate CVD
risk (22). The study hypothesis was that acute vascular function
was mediated by circulatory equol, especially endothelial
function (our primary outcome). We compared the vascular re-
sponse to a single dose of isoflavones in EPs and non-EPs
matched for cardiovascular-related factors determined a priori,
and subsequently investigated whether providing commercially
produced S-(–)equol supplements to non-EPs resulted in vas-
cular responses similar to those observed in EPs after con-
sumption of a daidzein-rich supplement.
METHODS
Study population
Healthy men aged 50–75 y who were screened to be at a 10–
20% 10-y absolute risk of CVD (22) were recruited by the re-
search scientists and research nurses. Ineligibility criteria were
as follows: history of smoking (recent past or present); a clinical
diagnosis of vascular disease, diabetes, or cancer; hepatic, renal,
digestive, hematologic, neurological, or thyroid disorders;
a resting BP .160/95 mm Hg at screening; and prescribed an-
tihypertensive, statin, or antibiotic medications.
To prospectively recruit EPs, a soy challenge was undertaken
according to standard methods (1); briefly, a commercially
available daidzein-rich soy protein bar providing w160 mg soy
isoflavones (aglycone equivalents), containingw64 mg daidzein
(Revival Products), was consumed daily over 3 consecutive
days, with urinary concentrations of equol and daidzein quan-
tified by using validated liquid chromatography–tandem mass
spectrometry (MS/MS) methods (23) from the first urine void on
the fourth morning (Figure 1). EPs were defined as urinary log10
S-equol/daidzein ratio $21.75, according to standard methods
(1). Subsequently, an independent scientist matched 14 EPs with
14 non-EPs, with the groups balanced for factors considered
likely a priori to affect vascular function, namely BMI and BP
(Figure 1). The allocation to treatment order was randomly
assigned by using a computer-generated, random-number se-
quence list.
The study was conducted at the Clinical Research and Trials
Unit between April 2012 and August 2013 (University of East
Anglia, United Kingdom) after National Research Ethics
Committee approval. The study followed the principles of the
Declaration of Helsinki and was registered at www.clinicaltrials.
gov (NCT01530893). Participants gave their informed written
consent before enrollment.
Study design
The study was conducted by using a randomized, double-blind,
placebo-controlled crossover design. Before each assessment
visit, a number of dietary and lifestyle restrictions were imple-
mented, including avoidance of flavonoid-containing supple-
ments (for $1 mo before and during the study), avoidance of
dietary flavonoids for 72 h (a list was provided), and avoidance
of strenuous exercise (for 48 h), caffeine, and alcohol (for 24 h).
Non–flavonoid-containing supplements (e.g., fish oils) were
maintained at habitual intake amounts throughout the study. To
control for the potential confounding effect on vascular function
of nitrate intake on circulating nitrite (NO2
2) and NO (24),
participants were also instructed to avoid NO2
2- and nitrate
(NO3
2)-rich foods (for 24 h; a list was provided) and to con-
sume low NO2
2- and NO3
2-containing commercially available
bottled water (Buxton; Nestle´ Ltd.). A standardized pasta meal
(Brake Bros Ltd.) was also provided, which was to be con-
sumed on the evening before each assessment visit. Habitual
dietary intakes were assessed by 24-h dietary recalls (assessed
by using standardized food intake software; WISP version 3.0;
Tinuviel).
Participants attended the clinical facility after a $10-h
overnight fast, and then underwent a standardized sequence of
vascular function assessments made at baseline and 6 and 24 h
after the intervention. Timings were selected to coincide with
peak plasma concentrations of isoflavones [i.e., daidzein and
genistein peak at w6 h (25, 26)] and metabolites [including
equol atw24 h (27)]. At each assessment time point, 15 min of
supine rest in a standardized quiet, light- and temperature-
monitored clinical room (21–248C) was followed by BP mea-
surements (taken in triplicate, each separated by 3 min) with the
use of an automated sphygmomanometer Omron 705IT (Omron
Health Care). Subsequently, carotid-femoral pulse-wave velocity
(cfPWV), cardiac output, and augmentation index were assessed
(Vicorder; Smart Medical), as described previously (references
28 and 29, respectively), and endothelial function (our primary
outcome measure) was measured via peripheral arterial to-
nometry, using finger plethysmography, to produce a reactive
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hyperemia index score (EndoPAT 2000; Itamar Medical), as
described previously (30). Blood samples were taken at the same
time points (baseline and at 6 and 24 h), and plasma was stored
at 2808C until subsequent concentration assessments of NO
(NO2
2 + NO3
2) and circulating isoflavone metabolites. Partic-
ipants were provided with a standardized lunch (cheese
sandwiches and vanilla yogurt, providing 31 g protein, 96 g car-
bohydrate, and 27 g fat; 753 kcal) 2.5 h after consumption of the
isoflavone or placebo capsules; no other food was provided before
this meal. Participants consumed another standardized pasta meal
and low-NO2
2/NO3
2 bottled water at home before returning in the
fasted state to the facility for their 24-h assessment.
An identical sequence of vascular function assessments was
made at the SE5-OH (commercial bacterium–produced equol)
assessment visit at baseline and at 2 h after the intervention; the
rationale for the shorter assessment was based on previous
pharmacokinetic studies that showed maximum synthetic equol
concentrations at 1–2 h after administration (8, 31).
Administration of intervention products and
treatment blinding
Intervention treatments were prepared by independent scien-
tists and provided to participants as opaque capsules (held within
opaque, tamper-evident bottles). A computer-generated, random-
sequence allocation list was produced by an independent scientist
and followed by the administrator of the treatments. The study
scientists conducting the vascular assessments and analyzing the
data remained blinded throughout the study.
Intervention products for isoflavone assessment
At each assessment, 1 of 2 interventions was administered
(following a randomly generated sequence, separated by$1 wk):
1) an isoflavone capsule providing 80-mg aglycone equivalents
of daidzein and genistein [a commercially available SoyLife
extract (40%) with a typical soy germ ratio of genistein:daidzein:
glycitein (15:50:35); Frutarom] or 2) a carboxy-methyl
FIGURE 1 Enrollment, randomization, and trial design. *Ten-year absolute percentage of cardiovascular disease risk calculated at screening by using the
British Hypertension Society risk calculator (22), incorporating plasma lipids, BMI, and SBP. CMC, carboxy-methyl cellulose; CV, cardiovascular; EP, equol
producer; SBP, systolic blood pressure.
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cellulose–containing placebo capsule. A dose of 80 mg iso-
flavones was chosen, because this represents the midpoint dose
from studies that previously showed improvements in endothelial
function (26, 32) and that is achievable through a diet containing
isoflavone-rich soy foods.
Intervention products for commercially produced S-(–)
equol assessment
To then determine the acute vascular effects of providing
commercially produced, bacterium-derived S-(–)equol supple-
ments (SE5-OH; Otsuka Pharmaceutical Co. Ltd.) to non-EPs,
a further intervention arm was conducted: a 40-mg S-(–)equol
dose was given to non-EPs and a placebo dose of carboxy-
methyl cellulose (matched for weight, color, and number of
capsules) was given as a control intervention to EPs. In previous
studies, maximum concentrations of 1.42 mmol/L in men (31)
and 4.95 mmol/L in postmenopausal women (8) were reported
1 h after the ingestion of 30 mg commercially produced equol
(SE5-OH). We chose a 40-mg dose of S-equol, because it was
previously shown to be bioavailable (33) and was considered
likely to attain plasma concentrations a priori in men, which
would be consistent with in vitro data showing NO-dependent
relaxation in endothelium-intact aortic rings [at concentrations
between 100 nmol and 10 mmol/L (34)] and a human in-
tervention study that showed NO-dependent vasodilation in
brachial arteries after the infusion of 3 mmol dehydroequol/L
(35).
Plasma isoflavone and NO analysis
Plasma isoflavones (daidzein, genistein, and glycitein) and the
metabolite equol were analyzed by using previously published
methods (23, 36). Briefly, plasma hydrolysis was performed by
using b-glucuronidase and sulfatase in phosphate buffer (pH 5)
with taxifolin as an internal standard; thereafter, the supernatant
was extracted via solid-phase extraction (Starta-X tubes; Phe-
nomenex; extraction efficiency of 81–92% over 3 replicates).
Extracts of 200 mL were then analyzed by using an Agilent 1200
series HPLC (fitted with a Kinetex PFP column; Phenomonex)
with a 3200 series Q-trap liquid chromatography–MS/MS sys-
tem (Sciex) and multiple-reaction monitoring. Analytes were
identified and quantified relative to pure standards by using
precursor and product transitions. The HPLC-electrospray
ionization-MS/MS methods were validated for linearity and pre-
cision with mean intra- and interassay precisions established as
12% and 11%, respectively.
Plasma samples were ultrafiltered (10 kDa) before duplicate
assessment for total NO concentrations (determined as the total of
NO2
2 + NO3
2) by using a commercial colorimetric assay
(product 780001; Cayman Chemical Co.). Intra- and interassay
CVs were 12.6% and 6.2%, respectively.
Sample size and statistical analysis
To detect a 0.35 increase in reactive hyperemia index (our
primary outcome measure) [assuming an SD of 0.4 on the basis
of previous data (37) with 80% power and at the 5% significance
level], a sample size of n = 14 participants/group was required to
complete the study. Data are presented as means 6 SEMs.
Baseline participant characteristics (EPs compared with non-
EPs) were assessed by using Student’s independent t tests, with
the Shapiro-Wilk test (for normality) and Levene’s test (equality
of variance for univariate analysis). At baseline, differences
between the intervention groups in plasma concentrations and
hemodynamic and vascular measures were evaluated by using
ANOVA. The primary intervention analysis was “change from
baseline” assessed by a mixed general linear model including
interaction between 1 within-subject factor (repeated-measure
ANOVA for treatment) and 1 between-subject factor (EP phe-
notype). All of the models were adjusted for age; BMI and
treatment order were not significant and were excluded from the
model. Bonferroni post hoc corrections were conducted where
significant between-group differences were identified. The
Spearman nonparametric test was used for bivariate correlations
between plasma equol and vascular endpoints because plasma
equol concentrations were not normally distributed. The treat-
ment effects of the commercially produced S-(–)equol supple-
ment was assessed via a general linear model (univariate
analysis), which accounted for EP phenotype as a between-
subject factor. Statistical analyses were performed by using
SPSS software (version 22), and P values , 0.05 were con-
sidered significant.
RESULTS
After a 3-d soy challenge, 33% of screened volunteers were
categorized as EPs and were matched for BMI and BP with non-
EPs (n = 14 EPs and n = 14 non-EPs completed the study; see
Figure 1). In the non-EP group, 2 additionally enrolled partici-
pants discontinued the study (after 1 experimental period) due to
a change in personal circumstances. No serious adverse events
were reported. Across the completers in both groups, mean 6
SEM age and BMI (in kg/m2) were 60 6 1 y (range: 50–70 y)
and 26.7 6 0.7 (range: 18.7–35.4), respectively, and the mean
British Hypertension Society algorithm–derived CVD risk was
15%, with no intergroup differences at baseline (Table 1).
cfPWV significantly decreased in EPs at 24 h after intake of
an isoflavone-rich capsule compared with after placebo (cfPWV
change from baseline: 20.2 6 0.2 m/s after isoflavone and
+0.6 6 0.2 m/s after placebo; P = 0.002) (Figure 2). Notably,
the highest plasma equol concentrations were attained in EPs
at 24 h (P , 0.01) (Table 2), and equol concentrations were
TABLE 1
Participant characteristics at baseline for the male EPs and non-EPs1
Non-EPs (n = 14) EPs (n = 14)
Age,2 y 62 6 2 (54–70) 57 6 1 (50–69)
BMI, kg/m2 25 6 1 26 6 1
Height, m 1.77 6 0.01 1.80 6 0.02
LDL cholesterol, mmol/L 3.82 6 0.20 3.86 6 0.21
Triglycerides, mmol/L 1.24 6 0.15 1.49 6 0.20
Systolic BP, mm Hg 133 6 2 131 6 3
Diastolic BP, mm Hg 80 6 1 81 6 2
Ten-year CVD risk,3 % 16 6 1 14 6 1
1Values are means 6 SEMs unless otherwise indicated. All P . 0.05,
except for age (P = 0.01) (Student’s independent t test). BP, blood pressure;
CVD, cardiovascular disease; EP, equol producer.
2Range in parentheses.
3The 10-y absolute cardiovascular disease risk as calculated using the
British Hypertension Society risk calculator (22).
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significantly correlated with changes in cfPWV (R = 20.36, P =
0.01). There were no cfPWV improvements for non-EPs at 24 h
after isoflavone intake (Figure 2). Likewise, neither EPs nor non-
EPs showed improved cfPWV values at 6 h (cfPWV change from
baseline to +6 h—EPs: +0.56 0.2 m/s after isoflavone and +0.26
0.2 m/s after placebo; NS; non-EPs: 20.3 6 0.2 m/s after
isoflavone and 20.1 6 0.2 m/s after placebo; NS).
As expected, plasma concentrations of daidzein, genistein, and
glycitein were significantly higher at 6 h after isoflavone in-
tervention (all P , 0.01; non-EPs: 301 6 40, 1692 6 269, and
2916 48 nmol/L, respectively; EPs: 2006 33, 16886 215, and
2376 36 nmol/L, respectively; Table 2); however, there were no
other effects observed for either EPs or non-EPs across the range
of vascular measures assessed at 6 or 24 h (Table 3). Likewise,
total NO concentrations (NO2
2 + NO3
2) were not significantly
different after isoflavone intake in EPs or non-EPs either at 6 or
24 h (total NO from baseline to 6 and 24 h after isoflavone
intake—EPs: +0.02 6 0.24 and 20.28 6 0.28, respectively;
both NS; non-EPs: +0.06 6 0.24 and 20.05 6 0.10, re-
spectively; both NS).
Although plasma equol concentrations in non-EPs reached
a mean of 3.2 mmol/L after intervention with commercially
produced S-(–)equol supplements (SE5-OH) (P , 0.001; non-
EPs: 3.22 6 0.47 mmol/L at 2 h), vascular function was not
significantly changed at +2 h (Table 4). For data regarding the
plasma isoflavone concentrations at 0 and 2 h after intake of
commercially produced equol and the plasma isoflavone con-
centrations at 0, 6, and 24 h after the intake of isoflavones and
placebo in EPs and non-EPs, see Supplemental Tables 1, 2, and
3 respectively.
DISCUSSION
In one of the first randomized controlled isoflavone trials to
prospectively recruit EPs to our knowledge, we observed acute
improvements in cfPWVafter soy isoflavone intakes at a dose
readily achieved through the habitual diet and provide evi-
dence of the potential significant importance of the EP phe-
notype. The potential clinical importance of this finding is
noteworthy given that cfPWV, a measure of arterial stiffness,
has been recently identified within the highest category of
surrogate markers of clinical endpoints (38) and was pre-
viously identified as an independent predictor of vascular
clinical outcomes (39). On the basis of previous data, which
suggest a 14–15% increase in CVD events and all-cause
mortality for each 1-m/s increment in cfPWV (40), our re-
sults would translate to an 11–12% risk reduction for middle-
aged men at moderate risk of CVD, if sustained. Of funda-
mental importance, cfPWV improved only in those with the
EP phenotype when there was a significant elevation in cir-
culating equol concentration (i.e., at 24 h); EP status con-
ferred no vascular benefits in the absence of equol (i.e., at 6 h),
FIGURE 2 Acute effect of isoflavone consumption after 24 h on cfPWV in EPs and non-EPs. Values are means 6 SEMs. Differences in study endpoints
between interventions were analyzed by using ANOVA, with changes from baseline assessed by using a mixed general linear model including interaction
between 1 within-subject factor (repeated-measures ANOVA for treatment) and 1 between-subject factor (EP phenotype). Bonferroni post hoc corrections
were conducted where significant between-group differences were identified. Further analysis with the use of repeated-measures ANOVA for intervention
effect (isoflavone compared with placebo in EPs for change from 0 to 24 h) was performed. ****P = 0.002 for cfPWV and P = 0.007 for S-equol. cfPWV,
carotid-femoral pulse-wave velocity; EP, equol producer; N.D., not detectable.
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despite significant increases in circulating concentrations of the
isoflavone precursors daidzein, genistein, and glycitein. These
data support the in vitro evidence that shows equol to have more
vasodilator capacity than its precursor, daidzein (12, 13). Pre-
vious studies have suggested that phosphorylation of endothelial
NO synthase, which subsequently increases the bioavailability
TABLE 3
Hemodynamic and vascular measures at 0 h and change from baseline at 6 and 24 h after placebo and isoflavone
intervention (80 mg isoflavones) in male EPs and non-EPs1
EP phenotype, treatment,
and time RHI Diastolic BP, mm Hg Systolic BP, mm Hg CO, L/min AI, %
EPs
Placebo
0 h 2.72 6 0.16 82 6 3 122 6 6 3.92 6 0.21 24 6 1
0–6 h 20.38 6 0.23 25 6 2 23 6 3 0.54 6 0.15 23 6 1
0–24 h 0.22 6 0.20 3 6 1 2 6 3 0.31 6 0.18 22 6 1
Isoflavones (80 mg)
0 h 2.62 6 0.17 83 6 3 123 6 6 4.09 6 0.21 25 6 1
0–6 h 20.46 6 0.27 26 6 2 23 6 3 0.56 6 0.24 23 6 1
0–24 h 0.33 6 0.18 0 6 2 2 6 3 0.11 6 0.17 23 6 1
Non-EPs
Placebo
0 h 2.57 6 0.15 76 6 2 128 6 2 4.30 6 0.18 26 6 2
0–6 h 0.39 6 0.22 24 6 2 22 6 3 0.18 6 0.15 22 6 1
0–24 h 0.05 6 0.19 2 6 1 1 6 3 20.06 6 0.18 21 6 1
Isoflavones (80 mg)
0 h 2.58 6 0.15 76 6 2 128 6 3 4.32 6 0.17 26 6 1
0–6 h 20.05 6 0.26 25 6 2 27 6 3 0.03 6 0.24 22 6 1
0–24 h 20.07 6 0.18 0 6 2 2 6 3 0.23 6 0.17 22 6 1
P 0.55 0.56 0.99 0.08 0.95
1Baseline values are means 6 SEMs; values for 0–6 h and 0–24 h are adjusted means 6 SEMs, with age used as
a covariate. n = 14/group, except for RHI [n = 13 (EPs) and n = 14 (non-EPs)]; 1 participant was excluded due to
incomplete occlusion during RHI assessment. Differences in study endpoints between interventions were analyzed by
using ANOVA, with changes from baseline assessed by using a mixed general linear model including interaction between
within-subject factor (repeated-measures ANOVA for treatment) and 1 between-subject factor (EP phenotype). Bonferroni
post hoc corrections were conducted where significant between-group differences were identified. Changes were considered
significant at P , 0.05. AI, augmentation index; BP, blood pressure; CO, cardiac output; EP, equol producer; RHI, reactive
hyperemia index.
TABLE 2
Plasma concentrations of isoflavones at baseline and 6 and 24 h postintervention in non-EPs and EPs after intake of
placebo or isoflavone (80 mg isoflavone as aglycone equivalents)1
Intervention, nmol/L
EP phenotype and isoflavone
Placebo Isoflavone supplement P
0 h 6 h 24 h 0 h 6 h 24 h 6 h 24 h
Non-EPs
Genistein 4 6 3 15 6 9 7 6 5 4 6 3 301 6 40 72 6 37 ,0.0001 0.093
Daidzein 4 6 2 16 6 7 8 6 4 4 6 2 1692 6 269 170 6 46 ,0.0001 0.002
S-equol ND ND ND ND ND ND NA NA
Glycitein 21 6 7 20 6 13 3 6 2 21 6 7 291 6 48 54 6 12 ,0.0001 ,0.0001
EPs
Genistein ND ND 3 6 3 ND 200 6 33 28 6 15 ,0.0001 0.11
Daidzein 1 6 1 3 6 2 4 6 2 1 6 1 1688 6 215 190 6 31 ,0.0001 ,0.0001
S-equol ND ND ND ND ND 236 6 81 NA 0.007
Glycitein 19 6 6 7 6 4 6 6 4 19 6 6 237 6 36 35 6 9 ,0.0001 0.009
1Values are means 6 SEMs; n = 14/group. P values represent the differences (by using ANOVA) in circulating
concentrations of isoflavones and equol between the isoflavone supplement and placebo groups at 6 and 24 h after
treatment. Isoflavone concentrations were significantly greater at 6 and 24 h after the isoflavone supplement in EPs and
non-EPs (P , 0.05 for all, except for genistein at 24 h and glycitein at 24 h in EPs; see Supplemental Table 2). Conversely,
there were no significant differences at either 6 or 24 h after consumption of placebo in EPs or non-EPs (P . 0.05 for all;
see Supplemental Table 3). EP, equol producer; NA, not applicable; ND, nondetectable or below the limit of detection.
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of NO, may be an important underlying mechanism for the
vascular bioactivity of equol (34, 35, 41); in particular, acute
inhibition of endothelial NO synthase has been shown to sig-
nificantly increase pulse-wave velocity, independent of BP
changes (42), which suggests the capacity for changes in NO
concentrations to regulate key vascular function, without af-
fecting BP. However, in our data set, we observed no effect of
acute isoflavone supplementation on total NO (NO2
2 + NO3
2),
suggesting either that chronic exposure to equol may be required
to modify NO production or metabolism or that other previously
reported mediators of arterial stiffness, such as vasoconstrictors
(endothelin), inflammation, oxidative stress, or the function of
smooth muscle cells (43), may be responsible for the acute ef-
fect we observed. Although there are currently insufficient data
to determine the effect of chronic equol exposure on NO pro-
duction, metabolism, and regulation, recent in vitro data support
an effect of equol on smooth muscle function (44).
Although we showed an improvement in cfPWV, an effect on
BP and endothelial peripheral arterial tonometry (measured by
using EndoPAT) was not observed in our acute study. Although
our findings are discrepant with previous cross-sectional or
retrospective analyses (3, 4, 7, 14, 15), our acute data confirm the
lack of effects on BP and flow-mediated dilation, which were
recently observed in prospectively recruited postmenopausal EPs
who consumed a daidzein-rich supplement for 6 mo (17). Taken
together, our data and those of Liu et al. emphasize the impor-
tance of confirming the effects of the EP phenotype in pro-
spectively recruited populations.
Interestingly, when we provided a commercially produced
S-(–)equol supplement (SE5-OH) at a dose of 40 mg S-(–)equol
to non-EPs we achieved a mean circulating equol concentration
in excess of other studies that provided SE5-OH [3.2 mmol/L in
our study compared with 1.42 mmol/L previously reported after
the intake of 30 mg S-(–)equol (31)]; however, circulating con-
centrations in our male population were still below concentrations
previously reported for postmenopausal women (4.95 mmol/L)
(8). Despite successfully elevating circulating equol concentra-
tions, we observed no significant vascular benefits 2 h after the
intake of commercially produced equol supplements [a time
chosen to coincide with peak plasma concentrations (8, 31)].
These findings imply that, at least in the acute setting, the EP
phenotype is a necessity to unlock the vascular benefits of elevated
equol concentrations. These findings are generally consistent with
a previous 12-wk intervention with SE5-OH in which male EPs
and non-EPs experienced no significant vascular improvements
(21); however, in the same study, female postmenopausal non-
EPs significantly reduced cardio-ankle vascular index (CAVI,
a measure of aortic stiffness) after consumption of 10 mg S-(–)
equol/d (21), suggesting potential differential effects by sex.
A strength of our trial is that, to our knowledge, it is one of the
only studies to date that has prospectively recruited EPs, rather than
using a retrospective post hoc analysis; the latter approach often has
insufficient power to establish EP status by treatment effects (as
a result of having unmatched EP and non-EP groups). In addition,
our assessment of vascular function at times that coincide with the
peak plasma concentration (6 and 24 h after intake) of the isoflavone
precursor and metabolite (equol) (4, 8, 27, 45, 46) allowed us to
confirm that the effects on cfPWVonly coincided with significantly
elevated equol concentrations, and not isoflavone parent com-
pounds; these data support earlier in vitro data on the greater bio-
activity of equol on vascular tissue response (i.e., cerebral artery)
(12) and vascular smooth muscle response (13) than its precursor,
daidzein. A potential limitation is that we only recruited men to
our study, and therefore could not further investigate the po-
tential sex disparities between EPs and vascular function
observed in previous studies (21). Furthermore, future studies
would benefit from extended assessments of vascular function
(beyond 24 h) on the acute effects of SE5-OH on EPs and non-
EPs using a crossover analysis design and on the sustained
exposure of EPs to isoflavones. In combination, such studies
would further elucidate the association between circulating
equol concentrations and vascular function.
Overall, this trial, which prospectively recruited EPs and non-
EPs, has provided evidence of the importance of the EP phe-
notype in mediating the favorable effects of dietary isoflavones
on vascular health. Importantly, in our data set, the EP phenotype
did not confer vascular benefits in the absence of equol, sug-
gesting that dietary or alternative means of enhancing the mi-
crobial production of equol are essential for EPs to gain vascular
benefits. Further data from long-term clinical trials that pro-
spectively recruit EPs are required to confirm whether the acute
improvements in cfPWV (which would equate to an 11–12% risk
reduction for CVD) are sustained and of long-term clinical
relevance.
TABLE 4
Hemodynamic and vascular measures at baseline and 2 h after non-EPs consumed a 40-mg equol supplement (SE5-OH)
and EPs consumed a matched placebo (containing CMC)1
EP phenotype
Non-EPs EPs P
0 h 0–2 h 0 h 0–2 h
RHI 2.78 6 0.14 0.40 6 0.23 2.71 6 0.17 20.09 6 0.23 0.16
Diastolic BP, mm Hg 80 6 2 1 6 2 78 6 2 0 6 2 0.76
Systolic BP, mm Hg 134 6 3 1 6 2 125 6 4 1 6 2 0.94
CO, L/min 4.60 6 0.25 20.17 6 0.17 3.93 6 0.27 0.03 6 0.17 0.44
AI, % 24 6 1 0 6 1 24 6 1 21 6 1 0.19
cfPWV, m/s 9.8 6 0.3 0.1 6 0.2 10.2 6 0.4 20.5 6 0.2 0.13
1Baseline values are means 6 SEMs; values for 0–2 h are adjusted means 6 SEMs, with age used as a covariate. n =
14/group. Differences in study endpoints between interventions were analyzed by using general linear model (univariate
analysis). AI, augmentation index; BP, blood pressure; cfPWV, carotid-femoral pulse-wave velocity; CMC, carboxy-methyl
cellulose; CO, cardiac output; EP, equol producer; RHI, reactive hyperemia index.
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